• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Medistem Advances Negotiations to License New Stem Cell Laboratories and Clinics in Europe, Asia and North America; Network of Laboratories and Clinics Would Conduct Stem Cell Research and Treatments With Proprietary Medistem Technologies

Posted on: Friday, 26 May 2006, 18:00 CDT

Medistem Laboratories, Inc. (OTCBB:MDSM) (FWB:S2U), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, has announced continued progress in its strategic goal to establish a series of international laboratory and clinical facilities to conduct research and fee-for-service treatments employing the Company's proprietary stem cell-based therapeutic technologies.

Medistem is currently in negotiations to license its technology to laboratories and clinics in locations around the world, including Germany, Switzerland, Bulgaria, Singapore, and Mexico. These negotiations would grant the international licensees the ability to further develop medically needed therapies based on Medistem's patent-pending, proprietary adult stem cell technologies, and enable fee-for-service patient treatments.

"We've made a great deal of progress in our program to expand our international licensees and create a network of first-class international affiliates," said Neil Riordan, Ph.D., Chairman, and CEO of Medistem.

The planned network of international licensees is a central element of Medistem's overall business vision to develop revenues through licensing its technologies to affiliates which will provide fee-for-service treatments.

Medistem has executed a technology licensing and royalty agreement with the Institute for Cellular Medicine (ICM) in San Jose, Costa Rica, which enables ICM to culture stem cells and work with physicians to develop and deliver Medistem's stem cell technologies and therapies. That facility is in the process of obtaining its license from the Health Ministry in Costa Rica.

Although Medistem has not yet begun marketing or advertising its technologies or the availability of therapeutic services, a substantial number of interested parties who have learned of the Company's technology initiatives have contacted Medistem and its affiliate, ICM, independently to inquire on treatment services. To date more than 100 inquiries have been made.

Initially, Medistem plans to focus on the development of stem cell-based therapeutics for a number of devastating neurological conditions which are currently incurable and difficult to treat. Central among Medistem's business and clinical initiatives is its planned launch of clinical trials to develop stem cell therapies to treat stroke, one of the most widespread causes of disability in the world, and for such neurological conditions as Parkinson's disease and cerebral palsy.

The Company also recently filed a U.S. patent application for stem cell based technology to treat lower back disorders by preventing spinal disc degeneration. Back pain disorders and complaints represent the second most common reason for doctor visits and cost the U.S. economy alone more than $50 billion annually. Medistem's novel technology is designed to address these problems through the application of regenerative stem cell-based medicine.

About Medistem Laboratories, Inc.

Medistem Laboratories is an innovative biotechnology company committed to the creation and commercialization of advanced medical therapies based on non-controversial adult stem cells. Medistem's corporate mission is to transform these stem cells into valuable medical treatments. The Company intends to create these treatments from adult stem cells derived from muscle, bone marrow and fat of adult patients seeking treatment, as well as from full-term, healthy placentas and umbilical cords, but not the controversial embryonic or fetal stem cells that are the focus of ethical and moral debates in some communities. The Company's business strategy calls for the establishment of a series of clinics and laboratories around the world to deliver unprecedented, next-generation cell therapies to help millions of patients. Initial development and treatment focus will use proprietary technology and cells sourced from umbilical cords, fat, bone marrow, and muscle for advanced treatment of cerebral palsy, stroke, cardiovascular disease and orthopedic diseases, primarily for the international marketplace. Additional applications ultimately will be targeted to the treatment of neurological disorders such as Parkinson's, Alzheimer's and certain types of cancer. Medistem believes it may hold a substantial competitive edge in the worldwide emerging market for stem cell-sourced medical solutions, positioning it to become a leading global provider of stem cell treatments on a fee-for-service basis, while accumulating intellectual property based on clinical and laboratory findings. For more information, please visit http://www.trilogy-capital.com/tcp/medistem/. To read or download Medistem's Investor Fact Sheet, please visit http://www.trilogy-capital.com/tcp/medistem/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/medistem/quote.html. Medistem is traded on the Frankfurt, Germany, stock exchange under the symbol S2U.

Cautionary Statement

This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements contained herein can be identified by the use of forward-looking terminology such as "believes,""expects,""may,""will,""should," or "anticipates," or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. We wish to caution the reader that these forward-looking statements that are not historical facts, are only predictions. No assurances can be given that the future results indicated, whether expressed or implied, will be achieved.

Source: Business Wire

More News in this Category